The enthusiasm for RNM vaccine technology is decreasing against the important scientific challenges and the growing public distrust. Analysis below by Jay Bhattacharya, new NIH director (National Health Institutes).
Jay Bhattacharya The new director of COVID Vaccine Consumption of NIH (National Institutes of Health) has decreased significantly in the United States, potentially marking the end of an era for this revolutionary but controversial technology. An in -depth analysis reveals the gaps between the theory and practical application of this medical platform.
A free fall adoption rate
COVID MRNA vaccines are experiencing a spectacular decrease in adoption rates. In the United States, very few people continue to receive thesis vaccines, and adhesion among children has never reached high levels, which, according to some experts, could be something good. In the public and market, these vaccines already seem obsolete. The income for Pfizer and Modern, which reached astronomical heights in 2021, have been collapsed since then.
The fundamental defects of RNM technology
The theory behind RNM vaccines seems simple: injecting RNM code that encourages cells to produce an antigen, which makes the immune system react and prepare against the target virus. However, reality presents three main problems:
- Uncontrollable dose: While the amount of injected RNM is controllable, the amount of antigens produced by the body is not absolutely. A single beach or RNA can generate a variable and unpredictable number or copies of antigen.
- Random distribution: Biodistribution of antigens in the body is not controlled, which could explain the advertising effects observed in different body systems.
- Imperfect fidelity: The proteins produced do not always correspond to the planned code. Reading frame changes and other anomalies can generate unwanted or incorrect antigens.
These deficiencies raise important regulatory questions: How can a product be approved when the dose is unknown, its distribution in the body is unpredictable and can produce involuntary substances?
Despite the Nobel Prize awarded by the initial advances in RNM technology, several important scientific advances seem necessary before this platform is ready for generalized and safe use.
